OHSU Knight Cancer Institute
ohsu.eduTotal trials
237
Active
59
Phase 3
2
Total enrollment
2,077,740
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 79 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Immune Checkpoint Inhibitor | — | — | — | — | — | 1 | |
| Fluciclovine PET/CT | — | — | — | — | — | 1 | |
| Piflufolastat | — | — | — | — | — | 1 | |
| Cytarabine | — | — | — | — | 12 | ||
| Prednisone | — | — | — | — | 5 | ||
| Venetoclax | — | — | — | — | 5 | ||
| Azacitidine | — | — | — | — | 3 | ||
| Oxaliplatin | — | — | — | — | 5 | ||
| Obinutuzumab | — | — | — | — | 3 | ||
| Daunorubicin | — | — | — | — | 2 | ||
| Tremelimumab | — | — | — | — | 2 | ||
| Methotrexate | — | — | — | 12 | |||
| Cyclophosphamide | — | — | — | 11 | |||
| Enzalutamide | — | — | — | 5 | |||
| Fluorouracil | — | — | — | — | 5 | ||
| Gemcitabine | — | — | — | — | — | 5 | |
| Pembrolizumab | — | — | — | — | 5 | ||
| Paclitaxel | — | — | — | 4 | |||
| Irinotecan | — | — | — | — | 3 | ||
| Leucovorin | — | — | — | — | 3 | ||
| Fludarabine | — | — | — | — | — | 3 | |
| Capecitabine | — | — | — | 3 | |||
| Leucovorin Calcium | — | — | — | — | 3 | ||
| Durvalumab | — | — | — | — | 3 | ||
| Irinotecan Hydrochloride | — | — | — | — | — | 2 | |
| Idarubicin | — | — | — | — | 2 | ||
| Ibrutinib | — | — | — | — | — | 2 | |
| Cladribine | — | — | — | — | — | 2 | |
| abiraterone acetate | — | — | — | — | 2 | ||
| Doxorubicin | — | — | — | — | 2 | ||
| Cabazitaxel | — | — | — | — | 2 | ||
| Ulipristal Acetate | — | — | — | — | — | 1 | |
| Floxuridine | — | — | — | — | — | 1 | |
| Carfilzomib | — | — | — | — | — | 1 | |
| Isatuximab | — | — | — | — | — | 1 | |
| Pomalidomide | — | — | — | — | — | 1 | |
| Losartan Potassium | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| ¹⁸F-Fluoromisonidazole | — | — | — | — | — | 1 | |
| Atorvastatin | — | — | — | — | — | 1 |
39 more active programs hidden
Next readouts
- 2019-10-16
- 2023-02-14
- 2024-06-10
- 2024-08-22
- 2024-09-25
- 2024-12-08
- 2025-06-30
- 2025-12-16
- 2026-03-08
- 2026-06-01
Top conditions
- Prostate Cancer15
- Leukemia13
- Malignant Solid Neoplasm12
- Lymphoma12
- Prostate Carcinoma12
- Breast Cancer12
- Breast Carcinoma9
- Myelodysplastic Syndromes8
Frequently asked questions about OHSU Knight Cancer Institute
- How many clinical trials does OHSU Knight Cancer Institute have on ClinicalTrials.gov?
- OHSU Knight Cancer Institute is listed as the lead sponsor on 237 clinical trials in ClinicalTrials.gov, 59 of which are currently active (recruiting, enrolling, or ongoing).
- How many of OHSU Knight Cancer Institute's trials are in Phase 3?
- 2 of OHSU Knight Cancer Institute's trials are in Phase 3, spread across 79 active drug programs.
- What therapeutic areas does OHSU Knight Cancer Institute focus on?
- OHSU Knight Cancer Institute's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Leukemia, Malignant Solid Neoplasm, Lymphoma, Prostate Carcinoma.
- When are OHSU Knight Cancer Institute's next clinical trial readouts?
- OHSU Knight Cancer Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer”, expected around 2019-10-16.